The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis.
In a murine model of experimental cutaneous leishmaniasis, we investigated the protection elicited by injection of histone H1 isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major. Partial protection was achieved in most of the animals as shown by reduction in lesion size, upon immunization with histone H1 or its peptides, provided that the region 1-60 was present in the molecule. These observations argue in favor of a thorough examination of the possibility of including histone H1 described here in a cocktail vaccine against human leishmaniasis.
Solioz
N
N
Institute of Biochemistry, University of Lausanne, CH-1066, Epalinges, Switzerland.
Blum-Tirouvanziam
U
U
Jacquet
R
R
Rafati
S
S
Corradin
G
G
Mauël
J
J
Fasel
N
N
D000818:Animals; D004195:Disease Models, Animal; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli; D005260:Female; D006657:Histones / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D015800:Protozoan Proteins / Q000276:immunology; D014614:Vaccines, Synthetic
D006657:Histones; D015800:Protozoan Proteins; D014614:Vaccines, Synthetic